Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-38922561

ABSTRACT

The resistance of malignant tumors to multiple drugs is a significant obstacle in cancer treatment and prognosis. Accordingly, we synthesized a celastrol (Cel) prodrug (Cel-CSO) by conjugating chitosan oligosaccharides (CSO) to Cel for reversing Taxol resistance in chemotherapy, followed by self-assembly with Taxol into a novel nanoplatform of Cel-CSO/Taxol nanoparticles (termed NPs). NPs showed a suitable size (about 153 nm), excellent stability and prolonged release of Cel and Taxol in a manner that depended on both pH and time. NPs effectively inhibited the overexpression of multidrug resistance-related protein P-gp, hypoxia inducible factor-1α (HIF-1α), and triggered the MCF-7/Taxol cell apoptosis through inhibiting the PI3K/AKT/NF-κB/HIF-1α pathway. In tumor-bearing mice, NPs exhibited significant curative effects in inducing apoptosis of MCF-7/Taxol tumors which showed a low expression level of P-gp, microtubule-related proteins TUBB3 and Tau. The results indicated that NPs may be a promising strategy to overcome drug resistance caused by P-gp, which improve the antitumor effects in drug-resistant breast cancer.

2.
Chem Res Toxicol ; 37(6): 944-956, 2024 Jun 17.
Article in English | MEDLINE | ID: mdl-38771988

ABSTRACT

Celastrol (Cel), extracted from Tripterygium wilfordii Hook, is a potential antiobesity drug, except for its adverse reactions in clinic. In the present study, we synthesized a promising celastrol-chitosan conjugate (Cel-CS1K) and evaluated its antiobesity effect and biological safety in diet-induced obese mice. Cel-CS1K showed higher drug loading (over 10 wt %), good solubility (18-19 mg/mL) in water, slower peak time (Tmax = 4 h), and clearance (T1/2 = 8.97 h) in rats. Cel-CS1K effectively attenuated the cytotoxicity, celastrol-induced apoptosis, and fat accumulation of hepatocytes. Cel-CS1K reduced body weight and dietary amount same as the free Cel but with lower toxicity in blood, liver, and testis. Cel-CS1K improved the glucose homeostasis, HDL-C level, insulin sensitivity, and leptin sensitivity, while it significantly reduced the gene expression levels of LDL-C, TG, and TC in obese mice. Furthermore, the adipose-related gene expression levels provided evidence in support of a role for Cel-CS1K in losing weight by the multimode regulation. Overall, Cel-CS1K provides a translatable therapeutic strategy for the treatment of diet-induced obese humans.


Subject(s)
Anti-Obesity Agents , Chitosan , Obesity , Pentacyclic Triterpenes , Triterpenes , Animals , Pentacyclic Triterpenes/pharmacology , Pentacyclic Triterpenes/chemistry , Obesity/drug therapy , Male , Triterpenes/chemistry , Triterpenes/pharmacology , Mice , Chitosan/chemistry , Chitosan/pharmacology , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/chemistry , Rats , Diet, High-Fat/adverse effects , Humans , Rats, Sprague-Dawley , Mice, Inbred C57BL , Apoptosis/drug effects , Tripterygium/chemistry
3.
Molecules ; 27(12)2022 Jun 08.
Article in English | MEDLINE | ID: mdl-35744811

ABSTRACT

Triptolide (TP) is a potential drug candidate for the treatment of cancer, but its use was hampered by its systemic toxicity and poor water solubility. Hence, a TP-CSO prodrug was synthesized by conjugating TP to chitosan oligosaccharide (CSO), and characterized by 1H NMR, FTIR, DSC and XRD analyses. The TP-CSO containing about 4 wt% of TP exhibited excellent water solubility (15 mg/mL) compared to TP (0.017 mg/mL). Compared with TP, the pharmacokinetics of the conjugate after oral administration showed a three-fold increase in the half-life in the blood circulation and a 3.2-fold increase in AUC (0-∞). The orally administered TP-CSO could more effectively inhibit tumor progression but with much lower systemic toxicity compared with TP, indicating significant potential for further clinical trials. In conclusion, CSO-based conjugate systems may be useful as a platform for the oral delivery of other sparingly soluble drugs.


Subject(s)
Chitosan , Diterpenes , Pancreatic Neoplasms , Phenanthrenes , Prodrugs , Chitosan/chemistry , Diterpenes/chemistry , Epoxy Compounds/chemistry , Epoxy Compounds/therapeutic use , Humans , Phenanthrenes/chemistry , Phenanthrenes/therapeutic use , Prodrugs/therapeutic use , Water , Pancreatic Neoplasms
4.
Drug Deliv ; 29(1): 89-98, 2022 Dec.
Article in English | MEDLINE | ID: mdl-34964425

ABSTRACT

Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application. Herein, we synthesized a Celastrol (Cel)-chitosan oligosaccharide (CSO) conjugate (Cel-CSO) for drug delivery. Celastrol was conjugated to a CSO backbone via amide bond formation, which was verified by infrared spectrum (IR) analyses. The Cel-CSO contained ∼10 wt% of Celastrol showed excellent aqueous solubility (18.6 mg/mL) in comparation with the parent Celastrol. Cel-CSO significantly inhibited tumor growth, induced apoptosis, and effectively suppressed tumor metastasis in human pancreatic cancer cells (BxPC-3). While the cytotoxicity of Cel-CSO in hepatic cells (HL7702) was lower than that of the free Celastrol. Cel-CSO enhanced the anticancer efficacy, promoted the circulation time of Celastrol, and reduced the subacute toxicity, which indicated that CSO can be a promising Celastrol delivery system for pancreatic cancer therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Chitosan/chemistry , Pancreatic Neoplasms/pathology , Pentacyclic Triterpenes/pharmacology , Animals , Antineoplastic Agents/administration & dosage , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Chemistry, Pharmaceutical , Drug Liberation , Humans , Mice , Mice, Inbred BALB C , Oligosaccharides/chemistry , Particle Size , Pentacyclic Triterpenes/administration & dosage , Solubility , Tumor Burden/drug effects
5.
Drug Deliv ; 27(1): 848-854, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32508161

ABSTRACT

The purpose of this study is to evaluate in vitro and in vivo antitumor efficacy and subacute toxicity of triptolide (TP) prodrug, a conjugate between TP and carboxymethyl chitosan (CC). The CCTP conjugate contained 4∼ wt % TP and displayed excellent aqueous solubility (5 mg/mL) as compared to the native TP (17 µg/mL). In vitro cytotoxicity of CCTP conjugate was evaluated by CCK8 assay against human pancreatic cancer (PC) cell lines, showing comparable the half maximal inhibitory concentration (IC50) values to the parent TP. In a mouse model of PC (BxPC-3), the CCTP conjugate administered orally (at dose levels as low as 0.2 mg TP equivalent/kg) showed comparable efficacy in reducing or eliminating xenograft tumor to the same dose of TP, but exhibited much lower subacute toxicity as seen in body weight loss and hematological toxicity.


Subject(s)
Chitosan/analogs & derivatives , Diterpenes , Phenanthrenes , Administration, Oral , Animals , Antineoplastic Agents, Alkylating/pharmacology , Antineoplastic Agents, Alkylating/toxicity , Biocompatible Materials/pharmacology , Cell Line, Tumor , Chitosan/pharmacology , Diterpenes/pharmacology , Diterpenes/toxicity , Drug Carriers , Drug-Related Side Effects and Adverse Reactions/prevention & control , Epoxy Compounds/pharmacology , Epoxy Compounds/toxicity , Humans , Inhibitory Concentration 50 , Mice , Pancreatic Neoplasms/drug therapy , Phenanthrenes/pharmacology , Phenanthrenes/toxicity , Prodrugs/pharmacology , Solubility , Treatment Outcome , Xenograft Model Antitumor Assays
6.
Pharmaceutics ; 12(3)2020 Feb 26.
Article in English | MEDLINE | ID: mdl-32110979

ABSTRACT

A new platform for triptolide (TP) delivery was prepared by conjugating TP to a carboxylmethyl chitosan (CMCS). Compared with the natural TP, the TP-conjugate (TP-CMCS) containing TP of ~5 wt% exhibited excellent aqueous solubility (> 5 mg/mL). Results of in vitro experiments showed that TP-CMCS could relieve TP-induced inhibition on RAW264.7 cells and apoptosis, respectively. Compared with the TP group, TP-CMCS could effectively alleviate the toxicity injury of TP and decreased the mortality rate of the mice (p < 0.05). TP-CMCS did not cause much damage to the liver (AST and ALT) and kidney (BUN and CRE) (p < 0.05). After administration, the levels of IL-6, IL-1ß, and TNF-α decreased, and the arthritis detumescence percentages increased significantly, and the bony erosion degree was distinctly decreased in the TP-CMCS groups and TP group. Our results suggested that TP-CMCS was a useful carrier for the treatment of RA, which enhanced aqueous solubility of free TP and reduced drug toxicity in vitro and in vivo.

SELECTION OF CITATIONS
SEARCH DETAIL
...